Table 4. Indications targeted by drug-related DCTs.
| Indications | DCT cases | |
|---|---|---|
| Psychiatry | ||
| Smoking cessation | 2 (23.7) | |
| Schizophrenia | 3 (3.2) | |
| Attention deficit hyperactivity disorder | 3 (3.2) | |
| Major depressive disorder | 3 (3.2) | |
| Drug abuse | 2 (2.2) | |
| Alcohol withdrawal | 1 (1.1) | |
| Cannabis use disorder | 1 (1.1) | |
| Anxiety disorder | 1 (1.1) | |
| Sleep disorder | 1 (1.1) | |
| Endocrinology | ||
| Diabetes | 8 (8.6) | |
| Dyslipidemia | 1 (1.1) | |
| Overweight | 1 (1.1) | |
| Post-menopausal osteoporosis | 1 (1.1) | |
| Infection | ||
| Human immunodeficiency virus prophylaxis | 6 (6.5) | |
| COVID-19 | 5 (5.4) | |
| Malaria chemoprevention | 1 (1.1) | |
| Malaria infection | 1 (1.1) | |
| Pulmonology | ||
| Asthma | 7 (7.5) | |
| Chronic obstructive pulmonary disease | 3 (3.2) | |
| Oncology | ||
| Breast cancer | 2 (2.2) | |
| Cancer (various) | 2 (2.2) | |
| Sickle cell anemia | 1 (1.1) | |
| Cardiology | ||
| Hypertension | 2 (2.2) | |
| Arrhythmia | 1 (1.1) | |
| Myocardial infarction | 1 (1.1) | |
| Neurology | ||
| Spinal cord injury | 2 (2.2) | |
| Cerebral palsy | 1 (1.1) | |
| Essential tremor | 1 (1.1) | |
| Dentistry | ||
| Cavity protection | 2 (2.2) | |
| Gingivitis | 1 (1.1) | |
| Gastroenterology | ||
| Bowel prep | 1 (1.1) | |
| Liver cirrhosis | 1 (1.1) | |
| Rheumatology | ||
| Raynaud’s disease | 1 (1.1) | |
| Dermatology | ||
| Rosacea | 1 (1.1) | |
| Ophthalmology | ||
| Dry eye | 1 (1.1) | |
| Pediatrics | ||
| Respiratory syncytial virus infection | 1 (1.1) | |
All data are expressed as a number (proportion %).
DCT, decentralized clinical trial; COVID-19, coronavirus disease 2019.